HUP0201480A3 - Treatment of refractory human tumors with epidermal growth factor receptor antagonists - Google Patents

Treatment of refractory human tumors with epidermal growth factor receptor antagonists

Info

Publication number
HUP0201480A3
HUP0201480A3 HU0201480A HUP0201480A HUP0201480A3 HU P0201480 A3 HUP0201480 A3 HU P0201480A3 HU 0201480 A HU0201480 A HU 0201480A HU P0201480 A HUP0201480 A HU P0201480A HU P0201480 A3 HUP0201480 A3 HU P0201480A3
Authority
HU
Hungary
Prior art keywords
treatment
growth factor
receptor antagonists
factor receptor
epidermal growth
Prior art date
Application number
HU0201480A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26978320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0201480(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of HUP0201480A2 publication Critical patent/HUP0201480A2/hu
Publication of HUP0201480A3 publication Critical patent/HUP0201480A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HU0201480A 1999-05-14 2000-05-01 Treatment of refractory human tumors with epidermal growth factor receptor antagonists HUP0201480A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31228499A 1999-05-14 1999-05-14
US37402899A 1999-08-13 1999-08-13

Publications (2)

Publication Number Publication Date
HUP0201480A2 HUP0201480A2 (en) 2002-08-28
HUP0201480A3 true HUP0201480A3 (en) 2009-03-30

Family

ID=26978320

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201480A HUP0201480A3 (en) 1999-05-14 2000-05-01 Treatment of refractory human tumors with epidermal growth factor receptor antagonists

Country Status (20)

Country Link
US (3) US20020012663A1 (OSRAM)
EP (2) EP1218032A4 (OSRAM)
JP (2) JP2003520195A (OSRAM)
KR (1) KR20020000223A (OSRAM)
CN (1) CN1200734C (OSRAM)
AU (1) AU782994C (OSRAM)
BG (1) BG106110A (OSRAM)
BR (1) BR0010524A (OSRAM)
CA (1) CA2373815A1 (OSRAM)
CZ (1) CZ20014083A3 (OSRAM)
EE (1) EE200100603A (OSRAM)
HK (1) HK1047236A1 (OSRAM)
HU (1) HUP0201480A3 (OSRAM)
IL (1) IL146480A0 (OSRAM)
MX (1) MXPA01011632A (OSRAM)
NO (1) NO20015546L (OSRAM)
PL (1) PL365999A1 (OSRAM)
RU (1) RU2294761C2 (OSRAM)
SK (1) SK16522001A3 (OSRAM)
WO (1) WO2000069459A1 (OSRAM)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
SK16522001A3 (sk) * 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
EP1236474A1 (en) * 2001-02-26 2002-09-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Negative regulation of epidermal growth factor receptor activity by Mig-6
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
CA2445898A1 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
RU2003134180A (ru) * 2001-05-08 2005-02-10 Мерк Патент ГмбХ (DE) Комбинированная терапия, использующая антитела к egfr и антигормональные средства
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
KR100719624B1 (ko) * 2001-05-18 2007-05-21 석정철 시각장애인을 위한 접착형 점자유도블록 및점자유도블록의 접착방법
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
CA2477932A1 (en) * 2002-03-08 2003-09-18 Axel Ullrich Use of egfr transactivation inhibitors in human cancer
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JPWO2004060400A1 (ja) * 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
WO2004073601A2 (en) * 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
CA2528961A1 (en) 2003-06-09 2005-01-06 Samuel Waksal Methods of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2540133A1 (en) * 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. Drugs for treating cancer
BRPI0415395A (pt) * 2003-10-15 2006-12-12 Osi Pharm Inc composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
AR048518A1 (es) 2004-04-02 2006-05-03 Osi Pharm Inc Inhibidores heterobiciclicos de proteina quinasas sustituidos con anillos 6,6 -biciclicos
EP1757609B1 (en) 2004-04-09 2013-10-16 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
AU2005249201A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
MXPA06014002A (es) * 2004-06-03 2007-02-08 Hoffmann La Roche Tratamiento con cisplatina y un inhibidor de cinasa del receptor del factor de crecimiento epidermico (egfr).
AU2005249205A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an EGFR-inhibitor
CN1960737A (zh) * 2004-06-03 2007-05-09 霍夫曼-拉罗奇有限公司 用奥沙利铂和egfr－抑制剂治疗
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626330A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug
WO2007049361A1 (ja) * 2005-10-27 2007-05-03 Stelic Corp. 肝線維化抑制剤
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
KR100723641B1 (ko) * 2006-06-07 2007-06-04 실버레이 주식회사 다중 조리가 가능한 솥
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2008046107A2 (en) * 2006-10-13 2008-04-17 The Regents Of The University Of California Novel inhibitors of the egfr kinase targeting the asymmetric activating dimer interface
MX338185B (es) * 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
EP2134854B1 (en) * 2007-03-15 2015-04-15 Ludwig Institute for Cancer Research Ltd. Treatment method using egfr antibodies and src inhibitors and related formulations
EA200901301A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Полипептиды, вариабельные домены антител и антагонисты
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
EP2220222A4 (en) * 2007-11-19 2011-10-12 Univ California NEW TEST FOR EGFR HEMMER
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
WO2009109605A1 (en) * 2008-03-05 2009-09-11 Novartis Ag Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
JP2012520893A (ja) 2009-03-18 2012-09-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
MA33198B1 (fr) * 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
RU2457546C1 (ru) * 2011-03-09 2012-07-27 Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) Способ моделирования аденокарциномы толстой кишки человека
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
JP2014531213A (ja) 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
MX377534B (es) 2014-02-28 2025-03-10 Tensha Therapeutics Inc Compuestos para usarse en el tratamiento de hiperinsulinemia.
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
AU2018302647B2 (en) * 2017-07-18 2025-04-10 Kyoto University Anti-human CCR1 monoclonal antibody
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4186567A (en) * 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US4510924A (en) * 1980-07-10 1985-04-16 Yale-New Haven Hospital, Inc. Brachytherapy devices and methods employing americium-241
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4763642A (en) * 1986-04-07 1988-08-16 Horowitz Bruce S Intracavitational brachytherapy
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
FI895955A7 (fi) 1988-04-15 1989-12-13 Protein Design Labs Inc Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita
AU627183B2 (en) 1988-04-16 1992-08-20 Celltech Limited Method for producing recombinant dna proteins
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP3039802B2 (ja) * 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5550114A (en) * 1993-04-02 1996-08-27 Thomas Jefferson University Epidermal growth factor inhibitor
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
KR100225721B1 (ko) * 1994-02-23 1999-10-15 디. 제이. 우드, 스피겔 알렌 제이 4-헤테로사이클릴-치환된 퀴나졸린 유도체, 이들의 제조 방법 및항암제로서의 용도
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5656655A (en) 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5468754A (en) 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2177925T3 (es) * 1996-01-23 2002-12-16 Novartis Ag Pirrolopirimidinas y procedimientos para su preparacion.
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
WO1997046684A1 (en) * 1996-06-06 1997-12-11 University Of Massachusetts Non-activated receptor complex proteins and uses thereof
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
SK16522001A3 (sk) * 1999-05-14 2002-10-08 Imclone Systems Incorporated Liečivo na inhibíciu rastu refraktérnych nádorov
NZ517150A (en) * 1999-08-27 2005-01-28 Genentech Inc Dosages for treatment with anti-ErbB2 antibodies
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
WO2002045653A2 (en) * 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
BRPI0210405B8 (pt) * 2001-06-13 2021-05-25 Genmab As anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
CA2477932A1 (en) * 2002-03-08 2003-09-18 Axel Ullrich Use of egfr transactivation inhibitors in human cancer
DE60326226D1 (de) * 2002-03-21 2009-04-02 Cayman Chemical Co Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
WO2003101491A1 (en) * 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
MXPA05003796A (es) * 2002-10-10 2006-02-22 Merck Patent Gmbh Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor.
US20060228355A1 (en) * 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
RU2390353C2 (ru) * 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her

Also Published As

Publication number Publication date
NO20015546D0 (no) 2001-11-13
CN1200734C (zh) 2005-05-11
US20020012663A1 (en) 2002-01-31
EE200100603A (et) 2003-02-17
JP2009120583A (ja) 2009-06-04
WO2000069459A1 (en) 2000-11-23
CA2373815A1 (en) 2000-11-23
CN1361700A (zh) 2002-07-31
EP1218032A1 (en) 2002-07-03
JP2003520195A (ja) 2003-07-02
EP2042194A3 (en) 2009-04-22
PL365999A1 (en) 2005-01-24
BG106110A (bg) 2002-04-30
KR20020000223A (ko) 2002-01-05
MXPA01011632A (es) 2002-11-07
RU2294761C2 (ru) 2007-03-10
US20030157104A1 (en) 2003-08-21
IL146480A0 (en) 2002-07-25
SK16522001A3 (sk) 2002-10-08
US20050112120A1 (en) 2005-05-26
AU782994C (en) 2006-08-24
HUP0201480A2 (en) 2002-08-28
NO20015546L (no) 2002-01-14
HK1047236A1 (zh) 2003-02-14
EP2042194A2 (en) 2009-04-01
EP1218032A4 (en) 2005-05-25
BR0010524A (pt) 2002-05-28
AU782994B2 (en) 2005-09-15
AU4687100A (en) 2000-12-05
CZ20014083A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
IL146480A0 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AU9500201A (en) Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
SI1119349T1 (sl) Antagonisti receptorja epidermalnega rastnega faktorja za zdravljenje hipersekrecije sluzi v pljučah
PL348634A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AU3968401A (en) System for warming lower extremities of supine persons
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
IL161865A (en) System for the stimulation of hair growth
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
SI1716853T1 (sl) Zdravljenje rakov äśloveĺ kega telesa z uporabo et743
HUP0104374A3 (en) Growth hormone releasing compounds and their antagonists for use for treatment of tumors
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
PL350890A1 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
ZA200110436B (en) Therapeutic use of melatonin.
AU2003236649A8 (en) Egf receptor antagonists in the treatment of gastric cancer
DE69933057D1 (de) Analoge des humanen basischen fibroblasten-wachstumsfactors
EP1181374A4 (en) NEW HUMAN AND MURINE KINASES
IL151992A0 (en) Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
ZA200109347B (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists.
HU0102696D0 (en) Use of growth hormone secretagogues for stimulating or increasing appetite
EP1210370A4 (en) TUMOR NECROSIS FACTOR TR16 HUMAN RECEPTOR
SI1242060T1 (sl) Zdravljenje metastatske bolezni
AUPQ421299A0 (en) Treatment of bone disorder
TW478344U (en) Improved suture scissors for medical use
HK1059886A (en) Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
TW379541U (en) Structure improvement of belt tip

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: IMCLONE LLC, US

Free format text: FORMER OWNER(S): IMCLONE SYSTEMS INCORPORATED, US

FD9A Lapse of provisional protection due to non-payment of fees